english.prescrire.org > Spotlight > 100 most recent > Paternal exposure to valproate drugs in the period prior to conception: neurodevelopmental disorders in children?

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Paternal exposure to valproate drugs in the period prior to conception: neurodevelopmental disorders in children?

 Adverse Effects   In 2023, epidemiological data suggesting an increased incidence of neurodevelopmental disorders in children whose father had taken a valproate drug during the 3 months prior to conception led several drug regulatory agencies to issue alerts about this potential risk. As of early 2024, what are the main evaluation data concerning this risk, how strong is the evidence they provide, and to what extent should they be taken into account in clinical practice?
Full article available for download by subscribers (3 pages)

©Prescrire 1 June 2024

Source: "Paternal exposure to valproate drugs in the period prior to conception: neurodevelopmental disorders in children?" Prescrire Int 2024; 33 (260): 159-161. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Valproic acid: the consequences
of in utero exposure, in brief"
Prescrire Int 2020;